Ditchcarbon
  • Contact
  1. Organizations
  2. Aurinia
Public Profile
Pharmaceutical Preparation Manufacturing
CA
updated 23 days ago

Aurinia Sustainability Profile

Company website

Aurinia Pharmaceuticals Inc., commonly referred to as Aurinia, is a biopharmaceutical company headquartered in Canada. Founded in 2013, Aurinia focuses on developing innovative therapies for autoimmune diseases, with a particular emphasis on lupus nephritis. The company has made significant strides in the industry, notably with the launch of its flagship product, LUPKYNIS™ (voclosporin), which offers a unique mechanism of action that enhances treatment options for patients. With a strong presence in North America and expanding operations in Europe, Aurinia has established itself as a leader in the autoimmune disease sector. The company’s commitment to research and development, coupled with its strategic partnerships, has positioned it favourably in the market, earning recognition for its contributions to patient care and treatment advancements.

DitchCarbon Score

How does Aurinia's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

27

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

31

Industry Benchmark

Aurinia's score of 27 is lower than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.

45%

Let us know if this data was useful to you

Aurinia's reported carbon emissions

In 2023, Aurinia Pharmaceuticals Inc. reported total carbon emissions of approximately 218,430 kg CO2e. This figure represents the company's global emissions, with no specific data disclosed for Scope 1 or Scope 3 emissions. In the previous year, 2022, Aurinia's emissions were primarily from Scope 2, totalling about 198,740 kg CO2e, while Scope 1 emissions were recorded at zero. Aurinia has not set specific reduction targets or initiatives as part of its climate commitments, nor does it participate in initiatives such as the Science Based Targets initiative (SBTi). The company’s emissions data is not cascaded from a parent organization, indicating that these figures are independently reported. Overall, Aurinia's emissions profile reflects a focus on managing its Scope 2 emissions, with a commitment to transparency in its reporting, although further climate action initiatives or reduction targets have yet to be established.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

2022
Scope 1
-
Scope 2
198,740
Scope 3
-

How Carbon Intensive is Aurinia's Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Aurinia's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is Aurinia's Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Aurinia is in CA, which has a very low grid carbon intensity relative to other regions.

Aurinia's Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

Aurinia has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare Aurinia's Emissions with Industry Peers

Bristol-Myers Squibb

US
•
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Horizon Therapeutics Public Limited Company

IE
•
Pharmaceutical Preparation Manufacturing
Updated about 2 months ago

Roche Holding AG

CH
•
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Eli Lilly and Company

GB
•
Pharmaceutical Preparation Manufacturing
Updated about 14 hours ago

Pfizer

US
•
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Vertex Pharmaceuticals

US
•
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251104.2
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy